172 related articles for article (PubMed ID: 21571768)
1. Rituximab treatment in patients with refractory inflammatory myopathies.
Mahler EA; Blom M; Voermans NC; van Engelen BG; van Riel PL; Vonk MC
Rheumatology (Oxford); 2011 Dec; 50(12):2206-13. PubMed ID: 21571768
[TBL] [Abstract][Full Text] [Related]
2. Rituximab as therapy for refractory polymyositis and dermatomyositis.
Noss EH; Hausner-Sypek DL; Weinblatt ME
J Rheumatol; 2006 May; 33(5):1021-6. PubMed ID: 16541475
[TBL] [Abstract][Full Text] [Related]
3. Rituximab for refractory polymyositis: an open-label prospective study.
Mok CC; Ho LY; To CH
J Rheumatol; 2007 Sep; 34(9):1864-8. PubMed ID: 17722224
[TBL] [Abstract][Full Text] [Related]
4. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population.
Unger L; Kampf S; Lüthke K; Aringer M
Rheumatology (Oxford); 2014 Sep; 53(9):1630-8. PubMed ID: 24706995
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry.
Couderc M; Gottenberg JE; Mariette X; Hachulla E; Sibilia J; Fain O; Hot A; Dougados M; Euller-Ziegler L; Bourgeois P; Larroche C; Tournadre A; Amoura Z; Mazières B; Arlet P; De Bandt M; Schaeverbeke T; Soubrier M
Rheumatology (Oxford); 2011 Dec; 50(12):2283-9. PubMed ID: 22019807
[TBL] [Abstract][Full Text] [Related]
6. A pilot trial of rituximab in the treatment of patients with dermatomyositis.
Chung L; Genovese MC; Fiorentino DF
Arch Dermatol; 2007 Jun; 143(6):763-7. PubMed ID: 17576943
[TBL] [Abstract][Full Text] [Related]
7. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate.
Rigby W; Ferraccioli G; Greenwald M; Zazueta-Montiel B; Fleischmann R; Wassenberg S; Ogale S; Armstrong G; Jahreis A; Burke L; Mela C; Chen A
Arthritis Care Res (Hoboken); 2011 May; 63(5):711-20. PubMed ID: 21557525
[TBL] [Abstract][Full Text] [Related]
8. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies.
Dastmalchi M; Grundtman C; Alexanderson H; Mavragani CP; Einarsdottir H; Helmers SB; Elvin K; Crow MK; Nennesmo I; Lundberg IE
Ann Rheum Dis; 2008 Dec; 67(12):1670-7. PubMed ID: 18272672
[TBL] [Abstract][Full Text] [Related]
9. [Refractory dermatomyositis associated with chronic organizing pneumonia treated with rituximab: report of one case].
Yáñez V J; Cisternas M M; Saldías H V; Saldías P F
Rev Med Chil; 2009 Jan; 137(1):88-93. PubMed ID: 19399327
[TBL] [Abstract][Full Text] [Related]
10. Rituximab therapy for refractory scleritis: results of a phase I/II dose-ranging, randomized, clinical trial.
Suhler EB; Lim LL; Beardsley RM; Giles TR; Pasadhika S; Lee ST; de Saint Sardos A; Butler NJ; Smith JR; Rosenbaum JT
Ophthalmology; 2014 Oct; 121(10):1885-91. PubMed ID: 24953794
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of allogeneic mesenchymal stem cell transplantation in patients with drug-resistant polymyositis and dermatomyositis.
Wang D; Zhang H; Cao M; Tang Y; Liang J; Feng X; Wang H; Hua B; Liu B; Sun L
Ann Rheum Dis; 2011 Jul; 70(7):1285-8. PubMed ID: 21622775
[TBL] [Abstract][Full Text] [Related]
12. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial.
Oddis CV; Reed AM; Aggarwal R; Rider LG; Ascherman DP; Levesque MC; Barohn RJ; Feldman BM; Harris-Love MO; Koontz DC; Fertig N; Kelley SS; Pryber SL; Miller FW; Rockette HE;
Arthritis Rheum; 2013 Feb; 65(2):314-24. PubMed ID: 23124935
[TBL] [Abstract][Full Text] [Related]
13. Strength in polymyositis and dermatomyositis: best outcome in patients treated early.
Fafalak RG; Peterson MG; Kagen LJ
J Rheumatol; 1994 Apr; 21(4):643-8. PubMed ID: 8035387
[TBL] [Abstract][Full Text] [Related]
14. Rituximab in the treatment of dermatomyositis: an open-label pilot study.
Levine TD
Arthritis Rheum; 2005 Feb; 52(2):601-7. PubMed ID: 15692974
[TBL] [Abstract][Full Text] [Related]
15. Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate.
Hengstman GJ; De Bleecker JL; Feist E; Vissing J; Denton CP; Manoussakis MN; Slott Jensen H; van Engelen BG; van den Hoogen FH
Eur Neurol; 2008; 59(3-4):159-63. PubMed ID: 18230873
[TBL] [Abstract][Full Text] [Related]
16. A pilot study: use of fludarabine for refractory dermatomyositis and polymyositis, and examination of endpoint measures.
Adams EM; Pucino F; Yarboro C; Hicks JE; Thornton B; McGarvey C; Sonies BC; Bartlett ML; Villalba ML; Fleisher T; Plotz PH
J Rheumatol; 1999 Feb; 26(2):352-60. PubMed ID: 9972969
[TBL] [Abstract][Full Text] [Related]
17. Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies.
Muñoz-Beamud F; Isenberg DA
Clin Exp Rheumatol; 2013; 31(6):896-903. PubMed ID: 24050676
[TBL] [Abstract][Full Text] [Related]
18. Effects of immunosuppressive treatment on interleukin-15 and interleukin-15 receptor α expression in muscle tissue of patients with polymyositis or dermatomyositis.
Zong M; Loell I; Lindroos E; Nader GA; Alexanderson H; Hallengren CS; Borg K; Arnardottir S; McInnes IB; Lundberg IE
Ann Rheum Dis; 2012 Jun; 71(6):1055-63. PubMed ID: 22267334
[TBL] [Abstract][Full Text] [Related]
19. Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow-up.
Hengstman GJ; van den Hoogen FH; van Engelen BG
Eur Neurol; 2004; 52(1):61-3. PubMed ID: 15240986
[No Abstract] [Full Text] [Related]
20. Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study.
Tobinai K; Igarashi T; Itoh K; Kurosawa M; Nagai H; Hiraoka A; Kinoshita T; Uike N; Ogura M; Nawano S; Mori S; Ohashi Y;
Cancer Sci; 2011 Sep; 102(9):1698-705. PubMed ID: 21645173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
